Foundry Healthcare IndMom Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $197.88B | 19.31% |
2DHR | DANAHER CORP | Healthcare | $144.26B | 14.07% |
3VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 12.03% |
4TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 3.64% |
5A | AGILENT TECHNOLOGIES INC | Healthcare | $37.13B | 3.62% |
6WAT | WATERS CORP | Healthcare | $36.23B | 3.53% |
7IQV | IQVIA HOLDINGS INC | Healthcare | $34.42B | 3.36% |
8ZTS | ZOETIS INC | Healthcare | $32.10B | 3.13% |
9VEEV | VEEVA SYSTEMS INC | Healthcare | $31.74B | 3.10% |
10ILMN | ILLUMINA INC | Healthcare | $28.24B | 2.76% |
11MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 2.58% |
12INCY | INCYTE CORP | Healthcare | $23.42B | 2.29% |
13UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 2.22% |
14VTRS | VIATRIS INC | Healthcare | $20.14B | 1.96% |
15MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 1.50% |
16EXEL | EXELIXIS INC | Healthcare | $14.06B | 1.37% |
17RVTY | REVVITY INC | Healthcare | $12.29B | 1.20% |
18TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 1.10% |
19CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $10.81B | 1.05% |
20TEM | TEMPUS AI INC | Healthcare | $9.42B | 0.92% |
21BRKR | BRUKER CORP | Healthcare | $8.86B | 0.86% |
22SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 0.85% |
23TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.82% |
24HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.80% |
25BIO | BIO-RAD LABORATORIES INC | Healthcare | $8.15B | 0.79% |
26HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.66% |
27XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 0.64% |
28SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $6.33B | 0.62% |
29TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.57% |
30TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.54% |
31TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.51% |
32VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.42% |
33WAY | WAYSTAR HOLDING CORP | Healthcare | $4.27B | 0.42% |
34TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 0.40% |
35DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.38% |
36SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.27% |
37VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.27% |
38TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.26% |
39TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.25% |
40ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.24% |
41VCEL | VERICEL CORP | Healthcare | $2.38B | 0.23% |
42PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 0.22% |
43OMCL | OMNICELL INC | Healthcare | $2.09B | 0.20% |
44URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.19% |
45TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.19% |
46NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.19% |
47ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.86B | 0.18% |
48STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.18% |
49ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.17% |
50TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.17% |
51VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.16% |
52XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.15% |
53AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.13% |
54XNCR | XENCOR INC | Healthcare | $1.30B | 0.13% |
55ABSI | ABSCI CORP | Healthcare | $1.29B | 0.13% |
56SVRA | SAVARA INC | Healthcare | $1.13B | 0.11% |
57NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.11% |
58WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.11% |
59EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.11% |
60CERT | CERTARA INC | Healthcare | $1.08B | 0.11% |
61VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.10% |
62TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.09% |
63HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.08% |
64ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.07% |
65PHR | PHREESIA INC | Healthcare | $662M | 0.06% |
66EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.06% |
67TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.06% |
68STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.06% |
69WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.06% |
70VSTM | VERASTEM INC | Healthcare | $530M | 0.05% |
71CTEV | CLARITEV CORP | Healthcare | $518M | 0.05% |
72ZURA | ZURA BIO LTD | Healthcare | $518M | 0.05% |
73XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.05% |
74NRC | NRC HEALTH | Healthcare | $491M | 0.05% |
75VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.04% |
76CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.04% |
77TENX | TENAX THERAPEUTICS INC | Healthcare | $420M | 0.04% |
78TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.04% |
79STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.04% |
80UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.04% |
81SLP | SIMULATIONS PLUS INC | Healthcare | $369M | 0.04% |
82ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.04% |
83VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.03% |
84TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.03% |
85MASS | 908 DEVICES INC | Healthcare | $278M | 0.03% |
86TTRX | TURN THERAPEUTICS INC | Healthcare | $272M | 0.03% |
87TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.03% |
88ZSQR | Z SQUARED INC | Healthcare | $260M | 0.03% |
89SRZN | SURROZEN INC | Healthcare | $255M | 0.02% |
90SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.02% |
91AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.02% |
92TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.02% |
93OWLT | OWLET INC | Healthcare | $162M | 0.02% |
94UNCY | UNICYCIVE THERAPEUTICS INC | Healthcare | $144M | 0.01% |
95VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.01% |
96OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
97VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.01% |
98XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.01% |
99TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.03T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 63% toward Growth. +6% unclassified (13 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 99 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual69.6%Margin-5.4%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 99 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 50.8% | 32.4% |
| 3 yearsp.a. | 4.3% | -3.5% |
| 5 yearsp.a. | -1.1% | -6.1% |
| 10 yearsp.a. | 6.3% | -4.5% |
| Since inceptionp.a. | 8.1% | -3.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 18.0% | 17.9% |
| 2025 | -0.2% | -20.1% |
| 2024 | -4.4% | -9.3% |
| 2023 | -4.3% | -6.4% |
| 2022 | -13.1% | -11.3% |
| 2021 | 15.6% | 5.5% |
| 2020 | 11.8% | -6.7% |
| 2019 | 27.2% | 3.1% |
| 2018 | 4.5% | -6.2% |
| 2017 | 28.6% | -5.5% |
| 2016 | -10.8% | -2.9% |
| 2015 | 3.2% | -3.5% |
| 2014 | 25.3% | -6.9% |
| 2013 | 45.3% | -3.4% |
| 2012 | 18.0% | 1.7% |
| 2011 | -3.5% | -14.0% |
| 2010 | 15.2% | 10.5% |
| 2009 | 23.9% | -12.8% |
| 2008 | -29.0% | -19.8% |
| 2007 | 3.4% | -0.6% |
| 2006 | 9.5% | -0.6% |
| 2005 | 17.1% | 1.9% |
| 2004 | 4.1% | -8.6% |
| 2003 | 16.7% | -23.1% |
| 2002 | -17.7% | 2.1% |
| 2001 | -3.0% | 8.7% |
| 2000 | 60.5% | -6.2% |
| 1999 | 3.3% | 24.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare IndMom Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a IndMom signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.